
BT8009 targets the tumor antigen Nectin-4, which has elevated expression levels in urothelial cancer.

BT8009 targets the tumor antigen Nectin-4, which has elevated expression levels in urothelial cancer.

The phase 3 URO-901-3005 study met its 2 co-primary end points with vibegron demonstrating a reduction in micturition episodes and urgency episodes from baseline to 12 weeks.

The EU application for erdafitinib in urothelial carcinoma is supported by data from cohort 1 of the phase 3 THOR trial.

Even before the pandemic, violence against health care workers was escalating.

Questions spanned urologic conditions such as benign prostatic hyperplasia, overactive bladder, erectile dysfunction, kidney stones, Peyronie disease, and recurrent urinary tract infections.

National MENtion It® campaign explores the impact stress has on men’s sexual and mental well-being.

"Am I close to an answer? Yes, my inner being tells me it is time to initiate letting go," says Gopal H. Badlani, MD.